Vascular smooth muscle cell-derived transforming growth factor-β promotes maturation of activated, neointima lesion-like macrophages

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 4, 2014, Pages 877-886

  Ostriker, Allison ^a   Horita, Henrick N ^a   Poczobutt, Joanna ^a   Weiser Evans, Mary C M ^a,b   Nemenoff, Raphael A ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

macrophages; muscle; neointima; smooth vascular; transforming growth factor beta; vascular system injuries

Indexed keywords

ARGINASE 1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR7; CHLORDANE; COLONY STIMULATING FACTOR 1; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL MATURATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOLOGY; EOSINOPHIL; FEMORAL ARTERY; FLOW CYTOMETRY; IN VITRO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; MONOCYTE MACROPHAGE PRECURSOR CELL; MONONUCLEAR CELL; MOUSE; NEOINTIMA; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR LESION; VASCULAR SMOOTH MUSCLE;

MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; TRANSFORMING GROWTH FACTOR BETA; VASCULAR SYSTEM INJURIES;

ANIMALS; BIOLOGICAL MARKERS; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYTOKINES; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARACRINE COMMUNICATION; PHENOTYPE; RATS; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR SYSTEM INJURIES;

EID: 84897390922     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303214     Document Type: Article

References (43)

1. Seedial SM, Ghosh S, Saunders RS, Suwanabol PA, Shi X, Liu B, Kent KC. Local drug delivery to prevent restenosis. J Vasc Surg. 2013;57:1403-1414.
2. Rodriguez-Menocal L, St-Pierre M, Wei Y, Khan S, Mateu D, Calfa M, Rahnemai-Azar AA, Striker G, Pham SM, Vazquez-Padron RI. The origin of post-injury neointimal cells in the rat balloon injury model. Cardiovasc Res. 2009;81:46-53.
3. Iwata H, Manabe I, Fujiu K, Yamamoto T, Takeda N, Eguchi K, Furuya A, Kuro-o M, Sata M, Nagai R. Bone marrow-derived cells contribute to vascular infammation but do not differentiate into smooth muscle cell lineages. Circulation. 2010;122:2048-2057.
4. Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat ML. Biological responses in stented arteries. Cardiovasc Res. 2013;99:353-363.
5. Jukema JW, Verschuren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol. 2012;9:53-62.
6. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol. 2006;59:232-239.
7. Simon DI. Infammation and vascular injury: basic discovery to drug development. Circ J. 2012;76:1811-1818.
8. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, Matsushima K, Sasayama S. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res. 1999;84:306-314.
9. Nemenoff RA, Horita H, Ostriker AC, Furgeson SB, Simpson PA, Vanputten V, Crossno J, Offermanns S, Weiser-Evans MCM. SDF-1α induction in mature smooth muscle cells by inactivation of pten is a critical mediator of exacerbated injury-induced neointima formation. Arterioscler Thromb Vasc Biol. 2011;31:2909-2919.
10. Schober A, Knarren S, Lietz M, Lin EA, Weber C. Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-defcient mice. Circulation. 2003;108:2491-2497.
11. Shagdarsuren E, Djalali-Talab Y, Aurrand-Lions M, Bidzhekov K, Liehn EA, Imhof BA, Weber C, Zernecke A. Importance of junctional adhesion molecule-C for neointimal hyperplasia and monocyte recruitment in atherosclerosis-prone mice-brief report. Arterioscler Thromb Vasc Biol. 2009;29:1161-1163.
12. Daniel JM, Bielenberg W, Stieger P, Weinert S, Tillmanns H, Sedding DG. Time-course analysis on the differentiation of bone marrow-derived progenitor cells into smooth muscle cells during neointima formation. Arterioscler Thromb Vasc Biol. 2010;30:1890-1896.
13. Danenberg HD, Fishbein I, Epstein H, Waltenberger J, Moerman E, Mönkkönen J, Gao J, Gathi I, Reichi R, Golomb G. Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery. J Cardiovasc Pharmacol. 2003;42:671-679.
14. Wainwright CL, Miller AM, Wadsworth RM. Infammation as a key event in the development of neointima following vascular balloon injury. Clin Exp Pharmacol Physiol. 2001;28:891-895.
15. Hong SJ, Ahn TH, Shim WJ, Park SM, Choi JI, Park JS, Lim SY, Lim D-S, Park CG, Seo HS. Macrophage depletion by clodronate liposomes suppresses neointimal formation after carotid artery injury in apolipoprotein e-defcient mice. Korean Circ J. 2013;38:244-249.
16. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G, De Baetselier P. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology. 2006;211:487-501.
17. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macro-phages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166-6173.
18. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G. Macrophage plasticity in experimental atherosclerosis. PLoS One. 2010;5:e8852.
19. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol. 2009;29:1419-1423.
20. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1506-1516.
21. Leitinger N, Schulman IG. Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:1120-1126.
22. Baetta R, Corsini A. Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis. 2010;210:1-13.
23. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953-964.
24. Boltz-Nitulescu G, Wiltschke C, Holzinger C, Fellinger A, Scheiner O, Gessl A, Förster O. Differentiation of rat bone marrow cells into macro-phages under the infuence of mouse L929 cell supernatant. J Leukoc Biol. 1987;41:83-91.
25. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest. 1991;88:904-910.
26. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci. 2003;116(Pt 2):217-224.
27. Ando H, Fukuda N, Kotani M, Yokoyama Si, Kunimoto S, Matsumoto K, Saito S, Kanmatsuse K, Mugishima H. Chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor-beta 1 mRNA inhibits neointima formation in rat carotid artery after balloon injury. Eur J Pharmacol. 2004;483:207-214.
28. Chung IM, Kim J, Pak YK, Jang Y, Yang WI, Han I, Park SJ, Park SW, Huh J, Wight TN, Ueno H. Blockade of TGF-β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances infammation in pig coronary arteries. Int J Cardiol. 2010;145:468-475.
29. LeClair RJ, Durmus T, Wang Q, Pyagay P, Terzic A, Lindner V. Cthrc1 is a novel inhibitor of transforming growth factor-beta signaling and neointi-mal lesion formation. Circ Res. 2007;100:826-833.
30. Smith JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, Koteliansky VE, Lindner V. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fbroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res. 1999;84:1212-1222.
31. Wan M, Li C, Zhen G, Jiao K, He W, Jia X, Wang W, Shi C, Xing Q, Chen YF, Jan De Beur S, Yu B, Cao X. Injury-Activated transforming growth factor β controls mobilization of mesenchymal stem cells for tissue remodeling. Stem Cells. 2012;30:2498-2511.
32. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A. Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol. 2002;22:940-948.
33. Yao EH, Fukuda N, Ueno T, Matsuda H, Nagase H, Matsumoto Y, Sugiyama H, Matsumoto K. A pyrrole-imidazole polyamide targeting transforming growth factor-beta1 inhibits restenosis and preserves endo-thelialization in the injured artery. Cardiovasc Res. 2009;81:797-804.
34. Moreno PR, Bernardi VH, López-Cuéllar J, Newell JB, McMellon C, Gold HK, Palacios IF, Fuster V, Fallon JT. Macrophage infltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation. 1996;94:3098-3102.
35. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229:176-185.
36. Suwanabol PA, Kent KC, Liu B. TGF-β and restenosis revisited: a smad link. J Surg Res. 2011;167:287-297.
37. Majesky MW. Choosing Smads: smooth muscle origin-specifc transforming growth factor-β signaling. Circ Res. 2013;113:946-948.
38. Guo X, Chen SY. Transforming growth factor-β and smooth muscle differentiation. World J Biol Chem. 2012;3:41-52.
39. Bogdan C, Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann N Y Acad Sci. 1993;685:713-739.
40. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137-161.
41. Ashcroft GS. Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect. 1999;1:1275-1282.
42. Pang Y, Gara SK, Achyut BR, Li Z, Yan HH, Day CP, Weiss JM, Trinchieri G, Morris JC, Yang L. TGF-β signaling in myeloid cells is required for tumor metastasis. Cancer Discov. 2013;3:936-951.
43. Ohashi N, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Miyamoto T, Nakano A, Sasayama S. Role of p38 mitogen-Activated protein kinase in neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol. 2000;20:2521-2526.